Alopecia–Intellectual Disability Syndrome

Alopecia–Intellectual Disability Syndrome is a very rare inherited condition. People with this syndrome have hair loss (sometimes on the whole body, sometimes only on the scalp, eyebrows, and eyelashes) together with intellectual disability that can range from mild to severe. In most families, the condition is autosomal recessive, which means a child must receive the changed gene from both parents. Doctors have reported only a small number of families in the medical literature, which is why information is limited and still growing. Some forms are present from birth; other signs (like more obvious hair loss or learning problems) may become clearer during early childhood. The hair changes and learning difficulties are not caused by poor care or environment; they come from changes in specific genes that guide hair-follicle biology and brain development. Orpha.net+2NCBI+2

Alopecia-intellectual disability syndrome is a very rare genetic condition. It mainly causes severe hair loss (often from birth or early childhood) and learning disability or developmental delay. Hair loss can be total (no scalp hair, eyelashes, or eyebrows) or partial. Some people also have seizures, delayed milestones, hearing problems, or tight muscles. Doctors have reported only a small number of families around the world with this condition, so information is limited. The condition is usually inherited in an autosomal recessive pattern (both parents carry one non-working copy of a gene). Genetic Diseases Center+1

---

Other names

Doctors and databases use several names for the same group of conditions:

• Alopecia–intellectual disability syndrome — newer, preferred wording.

• Subtype labels: APMR1, APMR2, APMR3, APMR4 (these mark different genetic forms). MalaCards+3NCBI+3MalaCards+3

• Alopecia-mental retardation (APMR) syndrome (older name; today we say “intellectual disability”). Several mapped types exist (APMR1–APMR4). KEGG+1

• APMR4 due to LSS variants (lanosterol synthase gene). This form often shows congenital alopecia with variable intellectual disability and sometimes epilepsy. PMC

• NSUN2-related intellectual disability (some individuals have marked hair changes along with developmental features). PMC+1

• Woodhouse-Sakati syndrome (DCAF17) is a different recessive disorder with progressive alopecia plus endocrine and neurologic features (it is part of the differential diagnosis when doctors see early alopecia with learning issues). NCBI+1

(“Woodhouse–Sakati syndrome” also features alopecia and intellectual disability, but it is a different disorder caused by DCAF17 variants and has extra endocrine and movement-disorder features; it is listed here only to help with differential diagnosis.) NCBI+1

---

Types

1) APMR1. A form mapped to chromosome 3q27; reports have described a pathogenic missense change in AHSG within this region in at least one family. Exact mechanisms are still being clarified. KEGG

2) APMR2. A second form mapped to chromosome 3q26.2–q26.31. The exact disease gene was not identified in the first families, but linkage studies firmly placed the locus here. PMC

3) APMR3. A third form mapped to chromosome 18q11.2–q12.2 in a large family. Again, the mapping is strong, but a single causal gene has not been pinned down in early reports. PMC

4) APMR4. A well-defined form caused by biallelic variants in LSS (lanosterol synthase), a key enzyme in the cholesterol-biosynthesis pathway. Individuals usually have congenital alopecia, variable intellectual disability, and may have developmental delay and epilepsy. This is an autosomal-recessive neuro-ectodermal syndrome. Frontiers+1

Why this matters: the hair follicle and the developing brain both depend on lipid/sterol pathways and tightly regulated cell signaling. In APMR4, LSS defects can disturb sterol balance, which helps explain both hair loss and neurodevelopmental features. For APMR1–3, the mapped regions highlight where future gene discoveries are expected. Frontiers

(Related/overlap note for clinicians): Pathways affecting RNA processing (e.g., NSUN2) can also produce intellectual disability with sparse hair in some patients, but those presentations are usually classified under NSUN2-intellectual disability syndrome (MRT5) rather than APMR. This is useful in the differential. PMC+2PMC+2

---

Causes

Primary genetic causes (established by human studies):

1. Biallelic LSS variants (APMR4) that reduce or change lanosterol synthase activity, disturbing cholesterol synthesis. Frontiers

2. APMR1 locus at 3q27, with a reported missense variant in AHSG within this mapped region in at least one family. KEGG

3. APMR2 locus at 3q26.2–q26.31 (gene not yet fully defined in early linkage reports). PMC

4. APMR3 locus at 18q11.2–q12.2 (gene not yet fully defined in early linkage reports). PMC

Mechanistic consequences that explain the clinical picture (how gene changes cause signs):

5. Disrupted sterol balance in skin impairs hair-shaft formation and hair-follicle cycling (seen in LSS-related disease). Frontiers

6. Altered cell-membrane and myelin lipid composition in the brain, affecting synapse and neural-network development (cholesterol pathway dependence). Frontiers

7. Faulty signaling between dermal papilla and hair-matrix cells, leading to miniaturized or absent follicles. (Biologic inference from sterol-pathway role.) Frontiers

8. Impaired epidermal barrier/lipid homeostasis, producing dry or scaly skin in some individuals. MalaCards

9. Loss-of-function variants causing truncated or unstable proteins (general mechanism across recessive genodermatoses). Frontiers

10. Missense variants that change enzyme kinetics or stability, reducing activity below a threshold needed for normal development. Frontiers

11. Homozygosity due to parental relatedness (consanguinity) increasing risk for recessive disorders in reported families. PMC

12. Modifier genes that can raise or lower severity of hair loss or learning problems within the same mapped subtype (explains variable expressivity). MalaCards

13. Epileptogenic susceptibility in LSS-related cases, likely secondary to abnormal cortical network development. Frontiers

14. Developmental-delay pathways downstream of disrupted sterol metabolism, affecting neuronal growth and connectivity. Frontiers

15. Keratinization pathway stress in follicles caused by lipid imbalance, worsening alopecia. MalaCards

16. Abnormal hair-shaft microstructure (seen on trichologic evaluation) reflecting upstream biosynthetic defects. MalaCards

17. Reduced hair-follicle density on histology in some cases. MalaCards

18. Increased fragility of growing hairs due to altered shaft composition. MalaCards

19. Secondary dermatologic irritation that can worsen breakage (not a root cause, but can aggravate hair loss). MalaCards

20. Nutritional shortfalls (for example, poor overall diet) do not cause APMR, but may worsen hair quality or cognition in any child; clinicians address them so they do not add to the genetic problem. (Clinical practice consideration.) MalaCards

Note: In APMR, the primary driver is genetic; items 5–19 describe how those genetic changes lead to hair and neurodevelopmental features, based on known roles of the affected pathways and observed phenotypes in published families.

---

Symptoms and signs

1. Hair loss on the scalp (partial or complete) starting at birth or early childhood. Orpha.net

2. Missing or very sparse eyebrows and eyelashes. NCBI

3. Sparse or absent body hair (axillary and pubic hair may be missing). MalaCards

4. Dry or scaly skin in some people (described especially in APMR4). MalaCards

5. Intellectual disability ranging from mild to severe. Orpha.net

6. Global developmental delay, especially in speech and language. Frontiers

7. Learning difficulties at school and need for special education support. Wiley Online Library

8. Epilepsy or seizures in a subset (more often reported in APMR4). Frontiers

9. Hypotonia (low muscle tone) and delayed motor milestones in some children. Frontiers

10. Behavioral or attention challenges linked to neurodevelopmental delay. Wiley Online Library

11. Small, fragile, or easily broken scalp hairs if any hair is present. MalaCards

12. Photosensitivity or scalp irritation after sun exposure (individual variation). MalaCards

13. Psychosocial stress related to visible hair loss and learning needs (important to address in care plans). Wiley Online Library

14. Normal growth or mild growth concerns (varies by subtype and family). Orpha.net

15. Otherwise normal internal organs unless another condition is present; this helps separate APMR from syndromes like Woodhouse–Sakati, which add endocrine and movement features. NCBI

---

Diagnostic tests

A) Physical examination (bedside assessments)

1. Focused scalp and body-hair exam. Doctor looks for pattern (scalp vs total-body), hair-shaft quality, and skin scale; this is the first clue to syndromic alopecia. Orpha.net

2. Eyebrow/eyelash inspection. Absent or sparse lashes/brows support the diagnosis in the right context. NCBI

3. Full skin exam. Dry/scaly skin or ichthyotic changes are documented, especially if APMR4 is suspected. MalaCards

4. Neurodevelopmental exam. Checks tone, reflexes, coordination, and practical skills to grade developmental delay. Wiley Online Library

5. Growth and nutrition assessment. Height/weight/head circumference plotted to identify co-factors that could worsen outcomes, even though they do not cause the syndrome. Wiley Online Library

B) “Manual” office tests (simple, hands-on procedures)

6. Hair-pull (tug) test. Gentle traction tests fragility and whether hairs come out easily, which supports a structural problem. MalaCards

7. Trichogram sampling. A few hairs are plucked and examined microscopically for shaft abnormalities. MalaCards

8. Standardized developmental screening tools (e.g., Ages & Stages, school-readiness checklists) to document delays and guide services. Wiley Online Library

9. Basic vision/hearing screening. Learning and behavior are affected by sensory deficits; screening ensures no added, fixable barriers. Wiley Online Library

10. Caregiver functional history. A structured history of milestones, seizure-like events, and learning support needs helps stage severity and plan care. Wiley Online Library

C) Laboratory and pathological tests

11. Genetic testing – targeted LSS sequencing and/or a multigene panel for congenital alopecia/intellectual disability. This is the key test when APMR4 is suspected. Frontiers

12. Whole-exome or genome sequencing. Used when panel testing is negative; can identify variants in known or new genes and clarify APMR1–3 families. PMC+1

13. Sanger confirmation and segregation analysis in the family to prove the variant tracks with disease in an autosomal-recessive pattern. Frontiers

14. Chromosomal microarray (homozygosity mapping). In consanguineous families, long homozygous stretches help localize the gene region (how APMR2/3 were first mapped). PMC+1

15. Skin biopsy (histology). May show reduced follicles or abnormal follicular structures; useful when genetic testing is pending or inconclusive. MalaCards

D) Electrodiagnostic tests

16. Electroencephalogram (EEG). Recommended if there are spells or developmental regression, because epilepsy can occur in APMR4. Frontiers

17. Evoked potentials (as indicated). Rarely used, but may help characterize neurodevelopmental involvement when MRI is nonspecific. Wiley Online Library

E) Imaging tests

18. Trichoscopy (dermoscopy of hair/scalp). Noninvasive imaging that shows hair-shaft and follicular-opening patterns supporting a structural alopecia. MalaCards

19. Brain MRI. Often normal or nonspecific, but done to rule out other causes of developmental delay and to complete the work-up when seizures are present. Wiley Online Library

20. Family carrier testing and prenatal options (when desired). Not imaging of the body, but “genetic imaging” of risk in a family—important for counseling because the condition is recessive. Frontiers

Non-pharmacological treatments (therapies and others)

Goal: support development, function, comfort, and appearance. No cure exists yet, but care can greatly improve quality of life.

1. Early intervention program: start therapy as soon as delays are seen.
   Purpose: maximize brain learning “windows.” Mechanism: repetitive, play-based skill building strengthens neural pathways.

2. Special education with individualized education plan (IEP):
   Purpose: match teaching to the child’s level. Mechanism: structured supports improve attention and learning.

3. Speech-language therapy:
   Purpose: improve understanding, speaking, and feeding. Mechanism: targeted exercises strengthen language and oral-motor planning.

4. Occupational therapy:
   Purpose: daily living skills (dressing, feeding). Mechanism: graded practice improves fine-motor control and independence.

5. Physiotherapy:
   Purpose: posture, balance, coordination. Mechanism: neuro-motor training increases strength and motor patterns.

6. Behavioral therapy (including CBT strategies adapted to level):
   Purpose: manage anxiety, tantrums, or rigid behaviors. Mechanism: teach coping and replacement skills.

7. Parent/caregiver training:
   Purpose: make home routines therapeutic. Mechanism: consistent strategies across settings reinforce skills.

8. Assistive communication (PECS, AAC devices):
   Purpose: give a voice when speech is limited. Mechanism: visual symbols or speech-generating tools support communication.

9. Visual/hearing supports:
   Purpose: correct sensory barriers to learning. Mechanism: glasses, hearing aids, or FM systems optimize input.

10. Nutritional counseling:
    Purpose: ensure protein, iron, zinc, vitamin D, B12 sufficiency. Mechanism: supports skin, hair, brain growth.

11. Scalp skin care:
    Purpose: protect bare scalp. Mechanism: gentle cleansers, emollients, and avoidance of irritants maintain skin barrier.

12. Sun protection:
    Purpose: prevent burns on hairless scalp. Mechanism: hats, UPF fabrics, broad-spectrum sunscreen.

13. Wigs/hair prostheses (pediatric-friendly):
    Purpose: appearance and self-esteem. Mechanism: cosmetic coverage; custom fittings improve comfort.

14. Scalp micropigmentation / cosmetic eyebrow micro-pigmentation:
    Purpose: visual density and facial framing. Mechanism: medical-grade tattooing creates the look of hair.

15. Psychological support / peer groups:
    Purpose: coping for child and family. Mechanism: reduces stigma and isolation.

16. Sleep hygiene plan:
    Purpose: behavior and learning improve with good sleep. Mechanism: consistent routines reset circadian rhythms.

17. Seizure safety education:
    Purpose: reduce injury risk. Mechanism: supervision, water safety, and rescue plans.

18. Dental and oral-motor care:
    Purpose: feeding comfort and speech clarity. Mechanism: regular dental care; exercises for chewing and saliva control.

19. School accommodations:
    Purpose: fair access to learning. Mechanism: extra time, simplified instructions, visual schedules.

20. Genetic counseling for the family:
    Purpose: understand inheritance, carrier testing, and future pregnancy options. Mechanism: informs decisions and enables prenatal or preimplantation testing. PMC

---

Drug treatments

Important safety note: No medicine cures the genetic cause of this syndrome. Medicines below target specific symptoms or complications (seizures, behavior, endocrine issues, sleep, skin comfort). Hair-growth drugs approved for alopecia areata (autoimmune) usually do not help congenital alopecia; if ever considered, this should be in a specialist setting or research protocol. FDA Access Data+1

1. Levetiracetam (antiepileptic).
   Dose: adults often start 500 mg twice daily; children weight-based. Timing: twice daily. Purpose: control seizures. Mechanism: modulates synaptic neurotransmission. Side effects: irritability, dizziness, somnolence.

2. Valproate (antiepileptic).
   Dose: 10–15 mg/kg/day start; titrate. Timing: divided doses. Purpose: broad seizure control. Mechanism: increases GABA. Side effects: weight gain, liver toxicity, teratogenicity (strict precautions).

3. Lamotrigine (antiepileptic).
   Dose: low start with slow titration. Purpose: seizures ± mood stabilization. Mechanism: sodium-channel modulation. Side effects: rash (rare SJS; slow titration reduces risk).

4. Melatonin (sleep).
   Dose: 1–3 mg at night (children often 1–5 mg; clinician-directed). Purpose: sleep onset. Mechanism: circadian signaling. Side effects: morning grogginess.

5. Methylphenidate (attention).
   Dose: low-dose start (e.g., 5–10 mg AM). Purpose: improve focus. Mechanism: dopamine/norepinephrine reuptake block. Side effects: appetite loss, insomnia.

6. Risperidone (behavioral dysregulation/irritability).
   Dose: 0.25–0.5 mg/day start; titrate. Purpose: reduce aggression/self-injury. Mechanism: dopamine/serotonin antagonism. Side effects: weight gain, EPS, prolactin rise.

7. Aripiprazole (behavior).
   Dose: 2 mg/day start; titrate. Purpose: irritability. Mechanism: dopamine partial agonist. Side effects: akathisia, GI upset.

8. Sertraline (anxiety/depression).
   Dose: 25–50 mg/day start. Purpose: mood/anxiety symptoms. Mechanism: SSRI. Side effects: nausea, sleep change, activation.

9. Baclofen (spasticity/hypertonia in some).
   Dose: 5 mg TID start. Purpose: relax muscle tone. Mechanism: GABA-B agonist. Side effects: sedation, weakness.

10. Clonidine (sleep/ADHD adjunct).
    Dose: 0.05 mg HS start. Purpose: sleep/impulsivity. Mechanism: alpha-2 agonist. Side effects: hypotension, sedation.

11. Topical emollients (ceramide/urea creams).
    Dose: apply 1–2×/day. Purpose: dry/scaly skin comfort. Mechanism: restore barrier. Side effects: rare irritation.

12. Hydrocortisone 1% cream (short course for irritated scalp skin).
    Use: thin layer for 5–7 days as directed. Purpose: itch/redness relief. Mechanism: anti-inflammatory. Side effects: thinning if overused.

13. Minoxidil topical (2–5%).
    Note: can help many hair-loss conditions but usually not effective when follicles are absent from birth; any trial should be specialist-guided. Dose: apply BID. Mechanism: follicle stimulation. Side effects: scalp irritation, unwanted body hair. PMC+1

14. Oral minoxidil (very low dose; specialist use only).
    Purpose: hair growth in selected conditions; not proven for congenital alopecia. Side effects: edema, tachycardia, hypertrichosis; requires monitoring. JAMA Network

15. Baricitinib (JAK inhibitor).
    Indication note: FDA-approved for severe alopecia areata (autoimmune), not for congenital APMR; off-label use is not recommended outside trials. Dose (AA): 2–4 mg daily in adults per label. Side effects: infection risk, lipids, liver enzymes (lab monitoring). FDA Access Data+2FDA Access Data+2

16. Topical ruxolitinib 1.5% cream (JAK inhibitor).
    Note: mixed evidence in alopecia areata; not established for congenital alopecia. Side effects: local irritation; systemic absorption is low. PubMed

17. Levothyroxine (if an overlapping syndrome shows hypothyroidism).
    Dose: weight-based, titrated to TSH/T4. Purpose: normalize thyroid. Mechanism: hormone replacement. Side effects: over-replacement causes palpitations, weight loss. NCBI

18. Sex-hormone replacement (only if a differential like Woodhouse-Sakati is confirmed with hypogonadism).
    Purpose: puberty induction and bone health. Monitoring: endocrine specialist. NCBI

19. Metformin or insulin (only if diabetes is present in a different, overlapping diagnosis). NCBI

20. Vitamin D/iron/zinc/B12 repletion when deficient.
    Purpose: correct aggravating factors for hair/skin and energy. Mechanism: restore normal physiology. Side effects: dose-related GI upset (iron, zinc).

---

Dietary molecular supplements

1. Protein (adequate daily intake): supports skin and hair keratin; helps growth and healing.

2. Iron (if low ferritin or anemia): supports hair cycling and oxygen delivery; too much iron is harmful—lab-guided only.

3. Zinc (if low): supports keratinocyte function and immune balance.

4. Vitamin D (if low): immune modulation and follicle cycling support.

5. Vitamin B12/folate (if low): DNA/RNA synthesis for fast-turnover tissues.

6. Omega-3 fatty acids: anti-inflammatory support for skin barrier and brain.

7. Biotin (only if deficiency or brittle-nail–hair syndrome; routine mega-doses are not helpful otherwise).

8. Selenium (if low): antioxidant enzyme support; avoid excess.

9. Copper (if low): hair pigment/structure enzymes; check levels first.

10. Multivitamin at RDA levels when diet is limited; avoid high-dose “hair vitamins” without medical reason.

---

Regenerative / stem-cell” options

There is no approved regenerative or stem-cell drug for alopecia-intellectual disability syndromes. Below are areas of research or cosmetic procedures, not cures. Use only under specialist care or in clinical trials.

1. Gene-targeted therapy (future concept): identifying the exact gene allows researchers to think about gene replacement/editing, but no clinical therapy exists yet for APMR.

2. Pathway-targeted therapy for LSS defects: scientists study sterol pathway modulation; no proven treatment yet. PMC

3. RNA-modifying therapy for NSUN2 pathways: theoretical; no clinical product yet. PMC

4. Wnt/follicle stem-cell pathway drugs: research stage in hair biology; not approved for congenital alopecia.

5. Platelet-rich plasma (PRP): cosmetic/dermatology use in some hair disorders; unlikely to help when follicles are absent from birth.

6. Scalp tissue engineering / hair-follicle neogenesis: exciting lab research; not available as standard care.

---

Surgeries / procedures

1. Scalp micropigmentation (medical tattoo):
   Procedure: tiny dots of pigment to simulate hair density. Why: cosmetic coverage for bare scalp when hair will not regrow.

2. Eyebrow micro-pigmentation or microblading:
   Procedure: creates natural-looking brows. Why: improves facial expression and confidence.

3. Custom wig or cranial prosthesis fitting (often with medical adhesive systems):
   Procedure: professional fitting and styling. Why: comfortable, natural appearance for daily life or special events.

4. Hair transplantation:
   Procedure: moving follicles from donor to bald areas. Why: Rarely suitable, because congenital alopecia often lacks robust donor hair or receptive scalp; a hair-transplant surgeon must assess candidacy.

5. Cochlear implant (only if significant sensorineural hearing loss is confirmed):
   Procedure: surgical hearing device. Why: improves access to sound and speech when hearing aids are not enough.

---

Prevention tips

1. Genetic counseling for parents and adult relatives.

2. Carrier testing in families with a known variant.

3. Prenatal or preimplantation genetic testing when a familial variant is known.

4. Avoid consanguineous marriages when possible to lower recessive-disease risk.

5. Early intervention enrollment to prevent secondary delays.

6. Ensure vaccinations and routine pediatric care.

7. Protect the scalp from sun (hats, sunscreen).

8. Treat iron, vitamin D, B12, zinc deficiencies if present.

9. Seizure safety planning to prevent injuries.

10. Mental-health support to prevent stigma, isolation, and school avoidance.

---

When to see doctors (red flags)

• No scalp hair or eyebrow/eyelash hair from birth or sudden loss in early infancy.

• Developmental delay (late sitting, walking, talking) or regression.

• Seizures, staring spells, or unusual movements.

• Hearing or vision concerns.

• Recurrent scalp sunburns, skin infections, or severe dryness.

• Behavior changes that affect learning or safety.

• Family planning questions (future pregnancies).

---

What to eat and what to avoid

What to eat:

• Balanced meals rich in protein (fish, eggs, dairy, legumes), iron (meat, beans, leafy greens), zinc (meat, lentils, seeds), B12/folate (meat, dairy, greens), and vitamin D (fortified foods, supervised sunlight, or supplements if low).

• Fruits, vegetables, whole grains, and healthy fats (olive oil, nuts) to support skin and brain.

• Fluids to prevent dehydration (helps skin).

What to avoid:

• Crash diets, very low-protein diets, and extreme elimination plans.

• High-dose “hair vitamins” without medical testing (risk of toxicity).

• Unregulated “stem-cell” or “immune booster” products marketed online.

• Harsh scalp chemicals and tight headwear that irritate the skin.

---

FAQs

1. Is this the same as alopecia areata?
   No. Alopecia areata is autoimmune. Alopecia-intellectual disability syndrome is genetic and usually present from birth or early childhood. JAK inhibitor pills like baricitinib are approved for alopecia areata, not for this syndrome. FDA Access Data

2. Can hair grow back?
   If follicles never formed or are severely under-developed, regrowth is unlikely. Cosmetic options (wigs, micropigmentation) help appearance and confidence.

3. How is the diagnosis confirmed?
   Through genetic testing (often exome sequencing or a focused gene panel). PMC

4. Which genes are known?
   The best-established subtype is APMR4 due to LSS. NSUN2 causes a related intellectual disability with hair changes. Other mapped regions (APMR1–3) exist but are rarer or less defined. PMC+1

5. How common is it?
   Extremely rare; only a small number of families have been reported worldwide. Genetic Diseases Center

6. Is it inherited?
   Usually autosomal recessive. Each parent is typically a healthy carrier; each pregnancy has a 25% chance for the condition.

7. What other problems can occur?
   Some have seizures, developmental delay, or skin dryness. Hearing issues are less common but checked. PMC

8. Are there cures?
   No cure yet. Care is supportive: therapies, education, seizure control if needed, scalp care, and cosmetic solutions.

9. Could thyroid or diabetes be part of this?
   Not typically in APMR forms, but Woodhouse-Sakati syndrome (a different disorder with progressive alopecia) has thyroid, diabetes, and hypogonadism; doctors rule this out if suspected. NCBI

10. Do hair-growth drugs help?
    Topical/oral minoxidil helps some hair-loss conditions, but usually not when follicles are absent from birth. Any trial should be specialist-guided. PMC

11. What about JAK inhibitors?
    Baricitinib is FDA-approved for severe alopecia areata, not for congenital APMR. Using it for APMR is experimental and generally not advised outside research. FDA Access Data

12. Can diet fix it?
    Diet cannot change the genes, but correcting deficiencies (iron, vitamin D, zinc, B12) supports overall health and skin.

13. What is the outlook?
    With early therapies, many children gain good functional skills. Hair loss is typically permanent but manageable with cosmetic options.

14. Can we plan a future pregnancy?
    Yes. Genetic counseling, carrier testing, and prenatal or preimplantation testing are available once the family’s variant is known.

15. Where can I read more?
    Clinical overviews and rare-disease summaries: Orphanet and GARD. For specific genetic subtypes: recent LSS (APMR4) and NSUN2 papers, and Woodhouse-Sakati (DCAF17) GeneReviews for the differential. NCBI+4Orpha.net+4Genetic Diseases Center+4

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 13, 2025.

PDF Documents For This Disease Condition References